Indian price control ''opera'' in court but confusion prevails
This article was originally published in Scrip
Executive Summary
Are India's apex pricing authority and the department of pharmaceuticals (DoP) on the same page with reference to the latest round of controversial price cap orders? Not really, if leading industry executives are to be believed.